Last reviewed · How we verify
Ddavp (DESMOPRESSIN)
Ddavp (Desmopressin) is a small molecule drug developed by Ferring Pharms Inc, targeting the vasopressin V1b receptor. It is a factor VIII activator, approved by the FDA in 1978 for treating hereditary factor VIII deficiency disease, nocturnal enuresis, partial central diabetes insipidus, polyuria, and von Willebrand disorder. Ddavp is off-patent with 23 generic manufacturers, and its half-life is approximately 3 hours with 15% bioavailability. Key safety considerations include fluid retention and hyponatremia. It is essential to monitor patients for signs of fluid overload and electrolyte imbalances.
At a glance
| Generic name | DESMOPRESSIN |
|---|---|
| Sponsor | Ferring Pharms Inc |
| Drug class | Factor VIII Activator |
| Target | Vasopressin V1b receptor |
| Modality | Recombinant protein |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1978 |
Approved indications
- Central Diabetes Insipidus
- Post-Trauma/Surgery Polyuria and Polydipsia
- Primary Nocturnal Enuresis
Common side effects
- hyponatremia
- hyponatremic convulsions
- water intoxication
Key clinical trials
- DDAVP for Pituitary Adenoma (NA)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency (NA)
- Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis (NA)
- NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden
- Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome (PHASE2)
- Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE (PHASE3)
- DDAVP Effect by TEG6 in Cardiac Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ddavp CI brief — competitive landscape report
- Ddavp updates RSS · CI watch RSS
- Ferring Pharms Inc portfolio CI